Regulatory milestones

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) gained $0.24 to $19.79 on Friday after partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a Type II variation application to EMA to expand the European label of Rienso ferumoxytol to include treatment of all adults with iron deficiency anemia who have a history of unsatisfactory oral iron therapy or cannot use oral iron. An sNDA for the indication has an Oct. 21 PDUFA date in the U.S.